Facile accelerated specific therapeutic (FAST) platform develops antisense therapies to counter multidrug-resistant...

Area of Science:

• Microbiology
• Molecular Biology
• Drug Discovery

Background:

• Multidrug-resistant (MDR) bacteria present a critical global health threat due to limited therapeutic options.
• Existing countermeasures struggle to keep pace with the emergence of antibiotic resistance.

Purpose of the Study:

• To develop a rapid platform for creating effective peptide nucleic acid (PNA) therapies against MDR bacteria.
• To demonstrate the efficacy of PNAs against challenging clinical isolates and explore novel delivery mechanisms.

Main Methods:

• The Facile Accelerated Specific Therapeutic (FAST) platform utilizes bioinformatics to design sequence-specific PNAs targeting bacterial genes.
• In-situ synthesis, validation, and efficacy testing of PNAs were performed.
• A novel delivery system repurposing the bacterial Type III secretion system was investigated.

Main Results:

• PNAs demonstrated significant growth inhibition in 82% of treatments against MDR clinical isolates, including carbapenem-resistant E. coli and K. pneumoniae.
• Nearly 18% of PNA treatments achieved >97% bacterial decrease.
• PNAs potentiated antibiotic activity and a novel delivery system eliminated 99.6% of intracellular Salmonella.

Conclusions:

• The FAST platform enables rapid development of targeted PNA therapies against MDR bacteria.
• PNAs show high efficacy in inhibiting bacterial growth and overcoming existing resistance mechanisms.
• A novel delivery system shows promise for intracellular bacterial infection treatment.